IGF1 CA repeat polymorphisms, lifestyle factors and breast cancer risk in the Long Island Breast Cancer Study Project

被引:54
作者
Cleveland, RJ
Gammon, MD
Edmiston, SN
Teitelbaum, SL
Britton, JA
Terry, MB
Eng, SM
Neugut, AI
Santella, RM
Conway, K
机构
[1] Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA
[3] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA
[4] Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY USA
[5] Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA
[6] CUNY Mt Sinai Sch Med, Dept Community & Prevent Med, New York, NY 10029 USA
[7] Pfizer Inc, Global Environm Safety & Risk Management, New York, NY USA
关键词
D O I
10.1093/carcin/bgi294
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Insulin-like growth factor I (IGF-I) is an important regulator of growth and differentiation and is a potent mitogen for human breast cancer cells. Recent investigations suggest an association between cytosine-adenine dinucleotide (CA)(n) repeat polymorphisms of the IGF1 gene and IGF-I levels and further evidence indicates that genotype may influence breast cancer risk. We assessed the relation between IGF1 (CA)(n) repeats and breast cancer, and evaluated modification of genotype effects according to traditional breast cancer risk factors in 1028 breast cancer cases and 1086 controls. An increased risk of breast cancer was seen for genotypes that included alleles with fewer than (CA)(19) repeats when compared to (CA)(19) repeat carriers, an association that was particularly strong among premenopausal women [odds ratio (OR) = 3.31; 95% confidence interval (CI) = 1.47, 7.48]. No significant association was observed between an IGF1 genotype with no (CA)(19) repeat compared to (CA)(19) repeat genotypes in either pre- or postmenopausal women overall. However, when traditional breast cancer risk factors were considered, premenopausal women with genotypes that lacked a (CA)(19) repeat had a nearly 60% increased risk of breast cancer among those who had ever used hormonal birth control, while never users had a significantly reduced risk (P-interaction = 0.01). Among postmenopausal women, those with genotypes lacking a (CA)(19) repeat allele had significantly increased breast cancer risk among subjects with a lower than median body mass index (BMI) (OR = 1.77 95% CI = 1.09, 2.87), while no association for IGF1 genotype was seen among women with a higher than median BMI (P-interaction = 0.04). Our results demonstrate a role for alleles with fewer than (CA)(19) repeats as a risk factor for breast cancer and also suggest that several traditional breast cancer risk factors modify the association of the IGF1 (CA)(19) repeat genotype.
引用
收藏
页码:758 / 765
页数:8
相关论文
共 57 条
[31]   Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: a cross-sectional study in healthy women [J].
Lukanova, A ;
Lundin, E ;
Zeleniuch-Jacquotte, A ;
Muti, P ;
Mure, A ;
Rinaldi, S ;
Dossus, L ;
Micheli, A ;
Arslan, A ;
Lenner, P ;
Shore, RE ;
Krogh, V ;
Koenig, KL ;
Riboli, E ;
Berrino, F ;
Hallmans, G ;
Stattin, P ;
Toniolo, P ;
Kaaks, R .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2004, 150 (02) :161-171
[32]   Nonlinear relationship of insulin-like growth factor (IGF)-I and IGF-I/IGF-binding protein-3 ratio with indices of adiposity and plasma insulin concentrations (Sweden) [J].
Lukanova, A ;
Söderberg, S ;
Stattin, P ;
Palmqvist, R ;
Lundin, E ;
Biessy, C ;
Rinaldi, S ;
Riboli, E ;
Hallmans, G ;
Kaaks, R .
CANCER CAUSES & CONTROL, 2002, 13 (06) :509-516
[33]   Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3 [J].
Ma, J ;
Pollak, MN ;
Giovannucci, E ;
Chan, JM ;
Tao, YZ ;
Hennekens, CH ;
Stampfer, MJ .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (07) :620-625
[34]   INSULIN-LIKE GROWTH-FACTORS AND CANCER [J].
MACAULAY, VM .
BRITISH JOURNAL OF CANCER, 1992, 65 (03) :311-320
[35]   A sequence repeat in the insulin-like growth factor-1 gene and risk of breast cancer [J].
Missmer, SA ;
Haiman, CA ;
Hunter, DJ ;
Willett, WC ;
Colditz, GA ;
Speizer, FE ;
Pollak, MN ;
Hankinson, SE .
INTERNATIONAL JOURNAL OF CANCER, 2002, 100 (03) :332-336
[36]  
Muti P, 2002, CANCER EPIDEM BIOMAR, V11, P1361
[37]   Effect of obesity on total and free insulin-like growth factor (IGF)-1, and their relationship to IGF-binding protein (BP)-1, IGFBP-2, IGFBP-3, insulin, and growth hormone [J].
Nam, SY ;
Lee, EJ ;
Kim, KR ;
Cha, BS ;
Song, YD ;
Lim, SK ;
Lee, HC ;
Huh, KD .
INTERNATIONAL JOURNAL OF OBESITY, 1997, 21 (05) :355-359
[38]   Growth hormone treatment induces mammary gland hyperplasia in aging primates [J].
Ng, ST ;
Zhou, JA ;
Adesanya, OO ;
Wang, J ;
LeRoith, D ;
Bondy, CA .
NATURE MEDICINE, 1997, 3 (10) :1141-1144
[39]   Leptin and insulin growth factor I in relation to breast cancer (Greece) [J].
Petridou, E ;
Papadiamantis, Y ;
Markopoulos, C ;
Spanos, E ;
Dessypris, N ;
Trichopoulos, D .
CANCER CAUSES & CONTROL, 2000, 11 (05) :383-388
[40]   EFFECT OF TAMOXIFEN ON SERUM INSULIN-LIKE GROWTH FACTOR-I LEVELS IN STAGE-I BREAST-CANCER PATIENTS [J].
POLLAK, M ;
COSTANTINO, J ;
POLYCHRONAKOS, C ;
BLAUER, SA ;
GUYDA, H ;
REDMOND, C ;
FISHER, B ;
MARGOLESE, R .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (21) :1693-1697